Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

211.92 +1.52 (+0.72%)
Official Closing Price Updated: 7:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
84 85 Next >
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Via The Motley Fool
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
Via The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
 
Via Benzinga
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025. 
Via Investor's Business Daily
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth. 
Via The Motley Fool
Neurocrine Wins FDA Approval For Genetic Disorder Drug
The company can launch within a week, says Chief Executive Kyle Gano. 
Via Investor's Business Daily
Analyst Scoreboard: 19 Ratings For AbbVie
 
Via Benzinga
Check Out What Whales Are Doing With ABBV
 
Via Benzinga
Check Out What Whales Are Doing With ABBV
 
Via Benzinga
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
Via The Motley Fool
Topics Stocks
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom improvement and safety. 
Via Benzinga
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
Alector's AL002 misses primary endpoint in Alzheimer's trial. BofA downgrades stock, cuts price target, and highlights near-term challenges. 
Via Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
 
Via Benzinga
3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer
Via The Motley Fool
It’s Been A Tough Month For Healthcare Stocks
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues. 
Via Talk Markets
Topics ETFs Stocks / Equities
Spotlight on AbbVie: Analyzing the Surge in Options Activity
 
Via Benzinga
(ABBV) - Analyzing AbbVie's Short Interest
 
Via Benzinga
Market Whales and Their Recent Bets on ABBV Options
 
Via Benzinga
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is cut by 17%. 
Via Benzinga
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
Via The Motley Fool
The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys
Via The Motley Fool
3 Dividend Stocks That Are Screaming Buys in November
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends. 
Via The Motley Fool
Unpacking the Latest Options Trading Trends in AbbVie
 
Via Benzinga
Where Will AbbVie Be in 5 Years?
Via The Motley Fool
AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like. 
Via Investor's Business Daily
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
 
Via Benzinga
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
The market was quiet today but we should still expect some gains through year -end albeit a bit choppy. 
Via Talk Markets
Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
84 85 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.